Opinion statement Nectin-4 is a tumor-associated antigen that is highly expressed on
various cancer cells, and it has been further proposed to have roles in tumor development …

Antibody–drug conjugates (ADCs) have transformed the treatment landscape in oncology
and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs …

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has
raised global concern. Although several papers have reviewed the current state of ADCs in …

Nectin-4 (Nectin cell adhesion molecule 4), a type I transmembrane cell adhesion protein,
was demonstrated to be overexpressed in a variety of tumors, making it an attractive antigen …

Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have
diversified treatments and improved responses and survival for chemotherapy refractory …

Background Enfortumab vedotin (EV) is an antibody‐drug conjugate directed against Nectin‐
4 that is used to treat urothelial carcinoma. Nectin‐4 is inherently expressed in the skin and …

The established cancer treatment strategy in clinical setting is based on chemo and
radiation therapy, having limitations due to severe side-effects and drug-resistance. Small …

This study aimed to investigate whether Enfortumab vedotin (EV) is suitable for patients with
locally advanced or metastatic urothelial carcinoma and to perform a meta-analysis of its …

Purpose: Nectin-4 is an overexpressed biomarker in 60-70% of triple-negative breast cancer
(TNBC), and an ideal target for radiotherapy and PET imaging. In this study, we have …

El melanoma, es un tumor maligno que surge de los melanocitos. Dada la capacidad de
células del melanoma de inactivar linfocitos, la inmunoterapia en melanoma se ha enfocado …